Vaccines · 2020 · 20 citations · 19 references
Life SciencesImmunologyInfectious DiseasesMolecular VirologyVaccinologyVirologyAntiviral ImmunityHiv Vaccine DevelopmentNanoparticle-based ImmunotechnologyVaccine PlatformsViral InfectionsViral VaccinesAntibodiesLipid NanoparticlesMosaic ImmunogensMrna DeliveryMrna FormulationT Cell Response InductionT-cell ImmunogenicityVaccine Immunogen Design
A vaccine will likely be one of the key tools for ending the HIV-1/AIDS epidemic by preventing HIV-1 spread within uninfected populations and achieving a cure for people living with HIV-1. The currently prevailing view of the vaccine field is to introduce protective antibodies, nevertheless, a vaccine to be effective may need to harness protective T cells. We postulated that focusing a T-cell response on the most vulnerable regions of the HIV-1 proteome while maximizing a perfect match between the vaccine and circulating viruses will control HIV-1 replication. We currently use a combination of replication-deficient simian (chimpanzee) adenovirus and poxvirus modified vaccinia virus Ankara to deliver bivalent conserved-mosaic immunogens to human volunteers. Here, we exploit the mRNA platform by designing tetravalent immunogens designated as HIVconsvM, and demonstrate that mRNA formulated in lipid nanoparticles induces potent, broad and polyfunctional T-cell responses in a pre-clinical model. These results support optimization and further development of this vaccine strategy in experimental medicine trials in humans.
19
Modified mRNA Vaccines Protect against Zika Virus Infection
Justin M. Richner, Sunny Himansu, Kimberly A. Dowd et al. · Cell · 2017 · 898 citations · Full text
Nilu Goonetilleke, Michael K. P. Liu, Jesus F. Salazar-Gonzalez et al. · The Journal of Experimental Medicine · 2009 · 643 citations · Full text